154 related articles for article (PubMed ID: 10725065)
21. The use of Sandimmun (cyclosporin A) in severe refractory rheumatoid arthritis: the Belgian experience.
Malaise MG; De Keyser P; De Backer M; van Lierde MA; Lesaffre E
Clin Rheumatol; 1995 Sep; 14 Suppl 2():26-32. PubMed ID: 8846651
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
[TBL] [Abstract][Full Text] [Related]
23. [Sandimmun-Neoral--a new quality of life for patients with severe systemic juvenile rheumatoid arthritis].
Alekseeva EI; Shakhbazian IE
Ter Arkh; 1999; 71(5):26-9. PubMed ID: 10399226
[TBL] [Abstract][Full Text] [Related]
24. [Passage from sandimmun to neoral in kidney transplantation in children].
Broyer M; Maisin A; Guest G; Baudouin V; Charbit M; Reigneau O; Loirat C
Arch Pediatr; 1999 Oct; 6(10):1066-9. PubMed ID: 10544781
[TBL] [Abstract][Full Text] [Related]
25. Clinical use of cyclosporin in rheumatoid arthritis.
Richardson C; Emery P
Drugs; 1995; 50 Suppl 1():26-36. PubMed ID: 8714796
[TBL] [Abstract][Full Text] [Related]
26. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
Marcos JC; Maccagno A; Gutfraind E; Garsd A; Messina DO; Maldonado Cocco J; Battagliotti C; Onetti CM; Tate G; Venarotti HO; Grosman H; Díaz EA; Otero AB
Medicina (B Aires); 2000; 60(4):435-40. PubMed ID: 11188947
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis.
Chawla M; Ali M; Marks R
Br J Dermatol; 1996 Sep; 135 Suppl 48():9-14. PubMed ID: 8881898
[TBL] [Abstract][Full Text] [Related]
29. Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies.
Colombo D; Egan CG
Int J Immunopathol Pharmacol; 2010; 23(4):1177-83. PubMed ID: 21244766
[TBL] [Abstract][Full Text] [Related]
30. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
Johns KR; Littlejohn GO
J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.
van den Borne BE; Landewé RB; Goei The HS; Rietveld JH; Zwinderman AH; Bruyn GA; Breedveld FC; Dijkmans BA
J Rheumatol; 1998 Aug; 25(8):1493-8. PubMed ID: 9712089
[TBL] [Abstract][Full Text] [Related]
32. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients.
Bistrup C; Nielsen FT; Jeppesen UE; Dieperink H
Nephrol Dial Transplant; 2001 Feb; 16(2):373-7. PubMed ID: 11158415
[TBL] [Abstract][Full Text] [Related]
33. Neoral (cyclosporin) in dermatology: technical aspects.
Smith SG
Br J Dermatol; 1996 Sep; 135 Suppl 48():2-4. PubMed ID: 8881896
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206
[TBL] [Abstract][Full Text] [Related]
35. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses.
Bourke JF; Berth-Jones J; Holder J; Graham-Brown RA
Br J Dermatol; 1996 Apr; 134(4):777-9. PubMed ID: 8733391
[TBL] [Abstract][Full Text] [Related]
36. [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
Wakasugi H; Yoshimoto M; Ono T; Muso E; Inui K
Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):792-7. PubMed ID: 12607968
[TBL] [Abstract][Full Text] [Related]
37. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. UK Neoral Study Group.
Moore RH
Transpl Int; 1996; 9 Suppl 1():S311-3. PubMed ID: 8959853
[TBL] [Abstract][Full Text] [Related]
38. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
Humbert H
Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.
Fu LW; Yang LY; Chen WP; Lin CY
Br J Rheumatol; 1998 Feb; 37(2):217-21. PubMed ID: 9569080
[TBL] [Abstract][Full Text] [Related]
40. Advantages of Neoral conversion in renal transplant patients.
Vennarecci G; Pisani F; Tisone G; Buonomo O; Famulari A; Casciani CU
Minerva Urol Nefrol; 1998 Jun; 50(2):161-4. PubMed ID: 9707972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
